In patients with tumor-cell PD-L1 ≥ 1%, NIVO + IPI had an OS benefit: the median OS increased by 11.2 months versus Chemo (20.2 vs. 9.0 months [refer to the figures for 95% CIs; hereinafter the same]), reducing the risk of death by 54% (HR 0.46 [0.30–0.71]) (Fig. 1a). Here, CD274 is linked to neoplasm.